NCT06913595

Brief Summary

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 25, 2024

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

March 24, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 6, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 25, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2025

Completed
Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

1.6 years

First QC Date

March 24, 2025

Last Update Submit

August 23, 2025

Conditions

Deep Venous Thrombosis

Outcome Measures

Primary Outcomes (1)

  • VENOUS THROMBOEMBOLISM

    DVT after bariatric surgery

    1 year

Study Arms (2)

Low Molecular Weight Heparin

ACTIVE COMPARATOR

Low molecular weight heparin as aprophylaxis after bariatric surgery

Drug: Low Molecular Weight Heparine

Direct Oral Anticoagulant.

EXPERIMENTAL

Direct Oral Anticoagulant as aprophylaxis after bariatric surgery

Drug: Direct Oral Anticoagulant.

Interventions

Direct Oral Anticoagulant.DRUG

Direct Oral Anticoagulant AFTER BARIATRIC SURGERY

Also known as: RIVROXABAN
Direct Oral Anticoagulant.
Low Molecular Weight HeparineDRUG

Low molecular weight heparin after bariatric surgery

Also known as: Enoxaparine
Low Molecular Weight Heparin

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • \- BARIATRIC PATIENTS

You may not qualify if:

  • BLEEDING TENDENCY

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, 11511, Egypt

Location

MeSH Terms

Conditions

Venous Thrombosis

Interventions

N(4)-oleylcytosine arabinosideEnoxaparin

Condition Hierarchy (Ancestors)

ThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Heparin, Low-Molecular-WeightHeparinGlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • mohammed elshwadfy

    Cairo University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of general surgery

Study Record Dates

First Submitted

March 24, 2025

First Posted

April 6, 2025

Study Start

March 25, 2024

Primary Completion

October 25, 2025

Study Completion

November 1, 2025

Last Updated

August 26, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)